Kodiak Sciences Inc.
NASDAQ:KODBiotechnology
-$0.03 today
- Market cap
- $6.40B
- Beta
- 2.21
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$3.73
Volume 0.74M
Average 1.10M
KOD Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Kodiak Sciences Inc.NASDAQ: KOD
Operating Expenses · Q3 FY2026 · quarter ended Sep 2026
Operating expenses grows, but more slowly than its trailing trend
Q3 FY2026 operating expenses of $67.1M rose 7.6% year over year, behind the +16.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at -10.8% a year.
Context
- Operating expenses increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +7.6% toward the trailing-twelve-month pace of +16.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 234.39M USD
- Year-over-year change
- +46.4%
- 4-year CAGR
- -2.4%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 234.39M | +46.4% |
| FY2024 | 2024-12-31 | 160.14M | -36.3% |
| FY2023 | 2023-12-31 | 251.37M | -23.9% |
| FY2022 | 2022-12-31 | 330.38M | +27.9% |
| FY2021 | 2021-12-31 | 258.34M | — |
Operating Expenses vs competitors
How KOD compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +16.0% is the 5th highest of 10, against a peer median of +14.9%.
- Over three fiscal years its annual growth of -10.8% compares with a peer median of +27.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $9.21B USD | +10.7% | +19.5% | 59.3% | |
| LTM Jun 2026 | $2.66B USD | -1.5% | +8.5% | 50.1% | |
| LTM Mar 2026 | $344.84M USD | +33.6% | +35.9% | 662.7% | |
| LTM Mar 2026 | $287.65M USD | +34.6% | +27.1% | 3777.4% | |
| LTM Sep 2026 | $251.17M USD | +16.0% | -10.8% | — | |
| LTM Mar 2026 | $168.56M USD | +86.2% | +93.2% | 191.0% | |
BLTEBelite Bio, Inc | LTM Sep 2026 | $132.58M USD | +96.2% | +87.3% | — |
| LTM Mar 2026 | $70.72M USD | +14.9% | -10.8% | 1583.9% | |
| LTM Mar 2026 | CHF 69.81M CHF | -10.3% | +34.7% | 13851.6% | |
| LTM Mar 2026 | $59.37M USD | -22.3% | +2.5% | 17821.9% | |
| Peer median (excluding KOD) | — | +14.9% | +27.1% | 1123.3% | |
Competitors are the stored peer set for KOD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 8.71M | 11M | 25.95M | 26.71M | 0 |
| Gross Profit | (8.71M) | (11M) | (25.95M) | (26.71M) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 217.34M | 267.59M | 206.3M | 126.1M | 182.37M |
| Selling, General & Admin | 41M | 62.79M | 71.02M | 34.05M | 52.02M |
| Operating Expenses | 258.34M | 330.38M | 251.37M | 160.14M | 234.39M |
| Depreciation & Amortization | 8.71M | 11M | 25.95M | 26.71M | 26.32M |
| EBITDA | (258.26M) | (322.8M) | (234.53M) | (149.5M) | (203.65M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (267.05M) | (341.38M) | (277.32M) | (186.85M) | (234.39M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 298K | 7.07M | 16.73M | 11.15M | 4.52M |
| Interest Expense | 22K | 18K | 13K | 0 | 0 |
| Other Income / Expenses | 61K | 7.56M | 16.83M | 10.64M | 4.42M |
| Income Before Tax | (266.99M) | (333.82M) | (260.49M) | (176.21M) | (229.97M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (266.99M) | (333.82M) | (260.49M) | (176.21M) | (229.97M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (5.16) | (6.39) | (4.97) | (3.35) | (4.32) |
| EPS (Diluted) | (5.16) | (6.39) | (4.97) | (3.35) | (4.32) |
| Weighted Avg Shares | 51.79M | 52.25M | 52.41M | 52.58M | 53.21M |
| Weighted Avg Shares (Diluted) | 51.79M | 52.25M | 52.41M | 52.58M | 53.21M |
Kodiak Sciences Inc.
NASDAQ:KOD
Intrinsic Alpha fair value
Locked
Current Price
$97.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.